SHANGHAI, China, March. 11, 2021 -- Genor Biopharma announced today that the preclinical progress of the company's leading preclinical drug candidates, GB261, GB262, GB263 and GB264 from its San-Francisco based bi-specific/tri-specific antibody platform, will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2021. The AACR annual meeting will be held between April 10th?and April 15th?and between May 17th?and 21th?online. Abstracts have been published on the AACR website.
?
Four Abstracts Published Online Below.
?
1. Title：A novel CD20/CD3 T cell engager designed from Rituximab targeting CD20+ cancer with multiple mechanisms
? ? Abstract Date and Time：8:00am – 11:59 PM EST, April 10th, 2021
?
2. Title：Development of a novel bispecific antibody targeting PD-L1 and CD55 for cancer therapy
? ? Abstract Date and Time：8:00am – 11:59 PM EST, April 10th, 2021
?
?
3. Title：Development of cMET/cMET/EGFR Trispecific antibody as therapeutic modality for Non-small Cell Lung Cancer
? ? Abstract Date and Time：8:00am – 11:59 PM EST, April 10th, 2021
?
?
4. Title：Development of Claudin 18.2/CD3 bispecific antibody maintaining effector functions for better cancer therapy
? ? Abstract Date and Time：8:00am – 11:59 PM EST, April 10th, 2021
?
?
